{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-053659","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.941264+00:00","generated_at":"2026-06-08T01:43:31.829402+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eterna Therapeutics expands license from Factor Bioscience, gains know-how and multi-tier sublicense rights","bullets":["Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.","CEO Matthew Angel is co-founder, President, CEO and director of Factor's parent company, creating a related-party transaction.","Licensor's termination rights are reduced; technology transfer to Eterna is now included subject to use restrictions.","Original agreement was from Feb 20, 2023, amended July 12, 2023; this restatement replaces it entirely."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-053659","json":"https://secwatch.observer/filing/0001140361-23-053659.json","markdown":"https://secwatch.observer/filing/0001140361-23-053659.md","text":"https://secwatch.observer/filing/0001140361-23-053659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/0001140361-23-053659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/ef20014811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:43:31.829402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f3e1e51ccd36c1e4e068fe68032e76214a32078","claim":"Ernexa Therapeutics Inc. entered into Exclusive Amended and Restated License Agreement with Factor Bioscience Limited (effective 2023-11-14).","evidence_excerpt":"On November 14 , 2023, Eterna Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Exclusive Amended and Restated License Agreement (the “A&R Agreement”) with Factor Bioscience Limited (“Factor”) to replace in its entirety the Exclusive License Agreement dated February 20, 2023","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/0001140361-23-053659-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Factor Bioscience Limited"},{"label":"Effective","value":"2023-11-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}